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Background: Chronic obstructive pulmonary disease (COPD) is a worldwide epidemic disease and a major cause of
death and disability. The present study aimed to elucidate pharmacological effects of adipose derived stromal cells
(ASCs) on pathological and biochemical factors in a guinea pig model of COPD. Guinea pigs were randomized into
5 groups including: Control, COPD, COPD + intratracheal delivery of PBS as a vehicle (COPD-PBS), COPD +
intratracheal delivery of ASCs (COPD-ITASC) and COPD + intravenous injection of ASCs (COPD-IVASC). COPD was
induced by exposing animals to cigarette smoke for 3 months. Cell therapy was performed immediately after the
end of animal exposure to cigarette smoke and 14 days after that, white blood cells, oxidative stress indices and
pathological changes of the lung were measured.
Results: Compared with control group, emphysema was clearly observed in the COPD and COPD-PBS groups
(p < 0.001). Lung histopathologic changes of COPD-ITASC and COPD-IVASC groups showed non-significant
improvement compared to COPD-PBS group. The COPD-ITASC group showed a significant increase in total WBC
compared to COPD-PBS group but there was not a significant increase in this regard in COPD-IVASC group. The
differential WBC showed no significant change in number of different types of leukocytes. The serum level of
malondialdehyde (MDA) significantly decreased but thiol groups of broncho-alveolar lavage fluid (BALF) increased
in both cell treated groups (p < 0.05 for all cases). Weight of animals decreased during smoke exposure and
improved after PBS or cell therapy. However, no significant change was observed between the groups receiving
PBS and the ones receiving ASCs.
Conclusion: Cell therapy with ASCs can help in reducing oxidative damage during smoking which may collectively
hold promise in attenuation of the severity of COPD although the lung structural changes couldn’t be ameliorated
with these pharmacological therapeutic methods.
Keywords: COPD, Stromal cells, Malondialdehyde, Thiol, Emphysema, WBC, Guinea pigs* Correspondence: boskabadymh@mums.ac.ir
1Neurogenic Inflammation Research Centre and Department of Physiology,
School of Medicine, Mashhad University of Medical Sciences, Mashhad
9177948564, Iran
Full list of author information is available at the end of the article
© 2014 Ghorbani et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Ghorbani et al. DARU Journal of Pharmaceutical Sciences 2014, 22:26 Page 2 of 12
http://www.darujps.com/content/22/1/26Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive lung disease. Its three most common pathological
changes are chronic bronchitis, chronic obstructive bron-
chiolitis and emphysematous destruction of the lung
parenchyma [1]. Emphysema, the main histopathologic
feature of COPD, leads to a decrease in elastic recoil and
therefore continuation of decrease in small airway patency
during expiration causing a not fully reversible airflow
limitation and increase in the lung residual volume [2].
This airway obstruction may contribute to respiratory fail-
ure and weight loss leading to cachexia [3] and eventually
death. Thus, finding a fundamental and curative approach
for this disease is of vital importance.
The other characteristic feature of COPD, as well as
other respiratory diseases, is the oxidant-antioxidant im-
balances. This imbalance is reported to be developed by
the increased lipid peroxidation which is known as an
index of oxidative stress and a reduction of antioxidant
capacity. Decrease in plasma protein sulfhydryl concen-
trations in COPD patients is well documented [4]. There
are also other evidences suggesting the role of reactive
oxygen species in lung inflammation of COPD patients
which can be a direct effect or through lipid peroxida-
tion products [5]. Therefore, increasing the antioxidant
capacity is one of the main concerns in the pharmaco-
logical treatment of COPD.
For treatment of such respiratory diseases as asthma,
bronchodilating agents are helpful but the airflow limi-
tation and accelerated loss of lung function caused by
COPD cannot be reversed by this type of treatments
[4,6]. The existing treatments for COPD only change
the symptoms, quality of life and exacerbation fre-
quency, while a fundamental or effective therapy is yet
to be achieved. Recent advances in regenerative medi-
cine and cell therapy have led to successful attempts
to restore damaged tissues. Therefore, cell-based ther-
apy might be a more promising therapeutic option for
COPD.
Adipose tissue derived stromal cells (ASCs) and
mesenchymal stem cells (MSCs), derived from ASCs
or bone marrow, are readily available sources of stro-
mal/stem cells required for cell therapy [5-10]. Many
researchers such as Schweitzer et al. [5], Ahmed et al.
[6], Gupta et al. [7], Baber et al. [8], Shigemura et al.
[9] and Ishiazwa et al. [10] have contributed to cell
therapy of lung diseases by local or systemic adminis-
tration of ASCs/MSCs to the animal model of differ-
ent lung injuries induced by elastase, monocrotaline
or endotoxin and have observed promising pharmaco-
logical effects.
The MSCs are reported to interfere with oxidative
stress and induce lung parenchymal regeneration [5,11].
Mesenchymal stem cells can ameliorate the pulmonarydamages by two mechanisms. One is protecting the vas-
cular bed endothelial cells from apoptosis by paracrine
effects of several growth factors such as Hepatocyte
growth factor (HGF) and Vascular endothelial growth
factor (VEGF). The other mechanism is acquiring the
phenotype or markers of airway or alveolar epithelial
cells and vascular endothelial cells. In addition, it has
been shown that transplantation of ASCs into elastase-
treated emphysema models augments alveolar and vas-
cular regeneration by enhancement of epithelial cell
proliferation, inhibition of alveolar cell apoptosis and
promotion of angiogenesis in lung vasculature [9,12].
Lung emphysematous destruction induced by COPD is
well studied by different studies. However, MSCs ameli-
orative effect on COPD in guinea pigs, the main model
of respiratory diseases, induced by cigarette smoking,
the main cause of COPD in human was not investigated.
On the other hand, some researches documented a
pharmacological protective effect on the epithelial cells
during oxidative damage by involvement of such cyto-
kines as insulin-like growth factor (IGF) [7,8], HGF [9],
and IL-6 [13] which raise the question if the MSCs may
exert their therapeutic effect by an antioxidant function
through secreting cytokines. There are few studies on
the topic of antioxidant function of stem cells such as
the one documenting that MSC protection of the kid-
neys against ischemia/reperfusion injury may be at least
in part due to their antioxidant effects [14]. Another
study also confirms an antioxidant along with a neuro-
protective function for MSCs which have been previ-
ously approved in an in vitro study on neuroblastoma
cells exposed to an oxidative stress [15]. However, such
studies aren’t formerly performed on the oxidative dam-
age induced in the lungs of COPD model guinea pigs.
Considering the pathological changes occurring during
COPD, at least three targets exist for intervention in-
cluding inflammation, emphysematous destruction, and
oxidative stress [5,14,15] among which the two latter
ones are the focus of this study.
As far as we know, there is no study to investigate the
ameliorative effect of ASCs on cigarette smoking-induced
lung injury in guinea pigs, the main animal model of
COPD. Therefore, the present study aimed to elucidate
the pharmacological effects of local and systemic injec-
tion of ASCs on oxidative factors, lung pathology and




Thirty one guinea pigs (600–800 g) were kept in a
temperature controlled room while a 12-h on/12-h off
light cycle was maintained. All animal experiments were
carried out according to the ethical guidelines of the
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ences. They were categorized to 5 groups as follows:
a) Control group, the animals were exposed to ambient
air rather than smoke (n = 6).
b) COPD group, the animals were exposed to cigarette
smoke for 3 consecutive months (n = 9).
c) COPD + PBS, the animals were exposed to cigarette
smoke and then received PBS as vehicle via
intratracheal injection (n = 5).
d) COPD + intratracheal delivery of ASCs (COPD-
ITASC), the animals were exposed to cigarette
smoke and then received 106 ASCs via intratracheal
injection (n = 6).
e) COPD + intravenous injection of ASCs (COPD-
IVASC): the animals were exposed to cigarette
smoke and then received 106 ASCs via intravenous
injection (n = 5).
Biochemical assays and lung pathological examination
were done 14 days after treatment with cell or vehicle.
Exposure of animals to cigarette smoke
Exposure of guinea pigs to cigarette smoke was performed
according to the method designed by Boskabady and Kiani
with some modifications [16]. Briefly, the animals were
placed in a special box which was divided into two parts:
one held the body of the animal and the other one held its
head (dimensions: 15×12×7 cm). Twenty millilitre puffs of
cigarette smoke were drawn out of the cigarettes using a
syringe and then exhausted at a rate of two puffs per mi-
nute into the animals’ head chamber (every 30 seconds,
one puff of cigarette smoke was dragged into the head
chamber). Exposure of animals to each cigarette lasted for
8–9 minutes, with a 10 minutes resting period between
two cigarettes. The animals were exposed initially to one
cigarette per day and gradually increasing to a maximum
of 5 cigarettes per day over a period of 20 days. In short,
the animals were exposed to cigarette smoke (Magna:
Nicotine = 5, tar = 6) for totally 3 consecutive months, 5
days per week, and 5 cigarettes per day (the cigarettes’
filters weren’t removed).
Preparation of stromal cells
Adipose tissues were obtained from healthy guinea pigs
weighing 600–800 g. They were anesthetized by intra
peritoneal injection of ketamine (150 mg/kg) and xyla-
zine (6 mg/kg). Subcutaneous inguinal fat deposits were
resected and under laminar hood, the fat tissue was
minced into 1–2 mm pieces by means of a sterile scalpel
[17]. The tissue pieces were incubated at 37°C for 60 mi-
nutes in PBS containing 2 mg/ml collagenase meanwhile
being shaken (60 cycles/min) [18,19]. After centrifuga-
tion (300 g for 8 minutes), the floated lipid layer wasdiscarded and the stroma-vascular fraction was collected,
washed and re-suspended in DMEM medium supple-
mented with 10% FBS, 100 units/ml penicillin and 100 μg/
ml streptomycin [19,20]. The cells were seeded into tissue
culture flask and passaged when 60–80% confluent and
used at passages three to six.
Differentiation of stromal cell
For differentiation to adipocyte, the stromal cells were
seeded in 12-well culture plate and then incubated in
DMEM supplemented with 3% FBS, 66 μM biotin, 250 μM
IBMX, 1 μM dexamethasone, 34 μM d-panthothenate,
5 μM indomethacin and 0.2 μM insulin. The cells were
maintained in differentiation medium for 3 days and then
exposed to the adipocyte maintenance medium consisting
of DMEM, supplemented with 3% FBS, 66 μM biotin,
1 μM dexamethasone, 34 μM d-panthothenate and 0.2 μM
insulin. After additional 9 days of incubation, adipogenesis
was confirmed by Oil Red O which stains intracellular
triglyceride droplets. For staining, the cells were fixed with
10% formalin and then incubated with Oil Red O solution.
Thereafter, the cells were washed three times with distilled
water and photographed using inverted microscope [19].
For osteocyte differentiation, the stromal cells were in-
cubated in DMEM supplemented with 10% FBS, 10 μg/ml
ascorbic acid, 5 mM β-glycerol phosphate and 0.1 μM
dexamethasone. The cells were maintained in the differen-
tiation medium for two weeks and the culture medium
was replaced every 3 days [21]. For Alizarin red staining,
the cells were fixed with 10% formalin and then incubated
with 2% Alizarin red solution. Thereafter, the cells were
washed three times with distilled water and photographed
using inverted microscope [22].
Stromal cell labeling and tracing
The cells were harvested, suspended in PBS and incu-
bated with 2 μM cell tracker CM DiI (Invitrogen) for
5 min in 37°C and 15 min in 4°C in the absence of light.
After 20 min of staining, it was centrifuged at 1500 for
5 min, washed with PBS, centrifuged again and suspended
in 0.3 ml PBS. It was finally dragged to a 27 gauge insulin
syringe and was prepared for injection to the animals’
jugular vein or trachea. After 2 weeks of ASCs administra-
tion (either intratracheal or intravenous), the animals were
euthanized and 4 μm sections were provided from differ-
ent regions of their lung. Existence of the CM-DiI labeled
stromal cells was detected under fluorescent microscope.
Intratracheal and systemic delivery of stromal cells
The guinea pigs of COPD-ITASC group were anesthe-
tized and after exposing the trachea, 0.3 ml PBS con-
taining 106 cells was injected under direct vision to the
trachea using a 27 gauge insulin syringe. Viability of
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with trypan blue staining.
In COPD-IVASC group, the animals were anesthetized
and the jugular vein was exposed. Then, a volume of
0.3 ml PBS containing 106 cells was injected into the
vein using a 27 gauge insulin syringe.Total WBC and differential WBC measurement
Total WBC was counted in duplicate in a hemocytometer
(in a Burker chamber) in blood stained with Turk solution
(1:10 dilution, consisted of 1 ml of glacial acetic acid, 1 ml
of gentiac vialet solution 1% and 100 ml distilled). Differ-
ential WBC was determined in blood samples stained with
Turk solution and Wright-Giemsa, respectively. Briefly,
differential cell counts were done on thin slide, prepared
with smearing blood sample, using Wright-Giemsa stain.
According to staining and morphological criteria, differen-
tial cell analysis was carried out under a light microscope
by counting 100 cells, and the percentage of each cell type
was calculated.Biochemical assays
After sacrificing the guinea pigs, broncho-alveolar lavage
fluid (BALF) was prepared from the lung by locating a
cannula into trachea and lavage of the lungs with 2 mL
of saline for 5 times (total: 10 mL). BALF was then centri-
fuged at 2500 × g for 10 min and the supernatant was
collected for measurement of thiol groups’ concentration.
Total thiol groups were measured using 2,2′-dinitro-
5,5′-dithiodibenzoic acid (DTNB) which reacts with the
SH groups to produce a yellow colored complex with
peak absorbance at 412 nm [23,24]. In summary, 1 mL
Tris-EDTA buffer was added to 50 μL of BALF and sam-
ple absorbance was read at 412 nm against Tris-EDTA
buffer alone (A1). Then, 20 μL of DTNB reagent (10 mM
in methanol) was added to the mixture and after 15 min,
the sample absorbance was again read (A2). Total thiol
concentration was calculated using this equation: Total
thiol (mM) = (A2-A1-blank) × 1.07/0.05 × 13.6.
Five ml blood sample was collected gently from the
left ventricle and placed in a citrate containing blood
collection tube not to be coagulated. The blood was cen-
trifuged and the serum was separated and kept in −70°C
for further measurement of MDA concentrations. MDA
level, as an index of lipid peroxidation, was measured.
MDA reacts with thiobarbituric acid (TBA) as a thiobarbi-
turic acid reactive substance (TBARS) to produce a red
colored complex which has peak absorbance at 535 nm.
Two mL from reagent of TBA/trichloroacetic acid (TCA)/
hydrochloric acid (HCL) was added to 1 mL of serum,
and the solution was heated in a water bath for 40 mi-
nutes. After cooling, the whole solutions were centrifuged
at 1000 g for 10 minutes. The absorbance was measuredat 535 nm [25]. The MDA concentration was calculated
as follows: C (m) = Absorbance/(1.56 × 105).
Lung pathology
After fixation of the lung specimen in formalin and staining
with H&E, the tissue sections were evaluated under a light
microscope by a pathologist. The pathologic changes in the
lung of COPD, COPD-PBS, COPD-ITASC and COPD-
IVASC groups were evaluated according to the intensity of
emphysema. Three intensities of parenchymal destruction
were considered for scoring the emphysema observed in
the lungs. Scoring of pathological changes was performed
as previously described [16]. For this purpose, the percent
of the area containing mild, moderate or severe emphy-
sema was multiplied by the number 1, 2 or 3, respectively
and the total score for each section was calculated.
Animals weight measurement
The weight of the animals of all groups was measured at
the beginning of the study (week 0) and after 3 months
(at the end of exposure period); but in COPD-PBS,
COPD-ITASC and COPD-IVASC groups, the weight of
animals was also measured after a further 2 weeks (at
the end of treatment with PBS or ASC cells).
Statistical analysis
All the data were quoted as mean ± SEM and compared
by means of Instat software. The data of COPD animals
were compared to the control ones using unpaired “t”
test. The same test was used for the comparison between
PBS and either COPD + ITASC or COPD + IVASC as
well as between COPD + PBS and COPD. In addition,
the comparison between the weights of animals at three
time points during the procedure was performed using
ANOVA. Significance was accepted at p < 0.05.
Results
Stromal cell characterization
Figure 1A and C shows the morphology of stromal cells
isolated from adipose tissue of guinea pig. The cells were
adherent and showed significant expansion in the cul-
tures (Figure 1A). After passage 3, they had a spindled,
fibroblast appearance in culture that is consistent with
MSCs morphology.
To determine whether the cells have pluripotent cap-
acity, before intratracheal or intravenous injection, a
number of them were cultured in differentiating media
specific for adipocyte and osteocyte. Oil Red O staining
showed the accumulated triglyceride droplets in the
cells cytoplasm which confirms adipogenic differenti-
ation capacity of the isolated stromal cells (Figure 1B).
In addition, Alizarin Red staining revealed extracellular
matrix mineralization which confirms osteogenic differ-
entiation capacity of the stromal cells (Figure 1D).
Figure 1 Differentiation of adipose derived stromal cells to adipocyte and osteocyte lineages. The stromal cells were cultured in
adipogenic or osteogenic differentiating media for 12 and 14 days, respectively. A: Oil Red O staining of cells cultured in control media; B: Oil Red
O staining of cultured cells in adipogenic differentiating media; C: Alizarin Red staining of cells cultured in control media; D: Alizarin Red staining
of cells cultured in osteogenic differentiating media. Magnification × 100.
Figure 2 Fluorescence microscopic photographs of lungs after intratracheal delivery of CMDiI-labeled stromal cells. A: Phase-contrast
microscopic image of lung from normal animal harvested 2 days after injection of labeled stromal cells into trachea (Magnification × 200); B: The
same field under fluorescent microscope. C: Phase-contrast microscopic image of formalin fixed lung from COPD animal harvested 14 days after
injection of labeled stromal cells into trachea (Magnification × 100); D: The same field under fluorescent microscope; E: Fluorescence microscopic
image of lung from COPD animal harvested 14 days after injection of PBS as vehicle (Magnification × 100).
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To detect stromal cells in airway structures, the CM-DiI
labeled cells were injected to trachea. Figure 2 shows
fluorescence microscopy of stromal cells after 2 or 14 days
of intratracheal delivery. Two days after intratracheal in-
jection, microscopic image of lung from normal guinea
pig (guinea pig experiencing no treatment) confirmed the
delivery of stromal cells into both large and small airway
structures (Figure 2A and B). The CM-DiI-labeled stromal
cells were also detected in the lung from COPD guinea
pig 14 days after intratracheal administration (Figure 2C
and D). There was no fluorescence signal in the lung har-
vested from COPD animal 14 days after injection of PBS
as vehicle (Figure 2E).
To ensure pulmonary delivery of stromal cells after
intravenous injection, fluorescence microscopy was also
done on lung sections two days after cell injection. The la-
beled cells were detected in the lung alongside resident
cells in airways and alveolar structures (Figure 3A and B).
In separate homing experiments, the labeled cells were
administered systemically via intravenous injection to a
COPD guinea pig. Fourteen days after administration of
the cells, fluorescence signals of labeled cells were still
detected in the lung (Figure 3C, D and E).Figure 3 Fluorescence microscopic photographs of lungs after system
homing of labeled stromal cells two days after injection of cells into jugula
C: Phase-contrast microscopic image of formalin fixed lung from COPD ani
jugular vein (Magnification × 100); D: The same field under fluorescent micr
microscope with magnification of × 400.Lung histopathological results
Three consecutive months of exposing animals to the
cigarette smoke caused a considerable destruction of
alveolar walls and consequently widespread emphysema
as H&E stained sections show. The same changes were
observed in the COPD-PBS group and there was no sig-
nificant difference between the emphysema score in
COPD-PBS and COPD groups. The change in emphy-
sema score of COPD-ITASC and COPD-IVASC animals
was non-significant compared to the COPD-PBS group
(Figure 4).
Biochemical results
BALF thiol concentration had a significant decrease in
COPD compared with control group (P < 0.001). There
was also a significant reduction in this factor in COPD-
PBS group compared to the COPD animals (P < 0.05). The
thiol concentration increased in both treated groups with
stromal cells, but it was only significant in COPD-IVASC
compared to COPD-PBS group (P < 0.05), (Figure 5).
Concentration of MDA had a significant increase in
the COPD group compared with the control animals
(P < 0.01) which was not significantly different with
COPD-PBS groups (Figure 6). The concentration of MDAic delivery of CMDiI-labeled stromal cells. A and B: Lung
r vein of normal guinea pig (Magnification: A = ×100, B = ×400);
mal harvested 14 days after injection of labeled stromal cells into



















Figure 4 Effect of adipose derived stromal cells (ASCs) therapy on pathological changes of the lung according to the scoring method
mentioned in the text. Data are shown as mean ± SEM. ***P < 0.001 as compared with control group. The animals in COPD-PBS, COPD-ITASC
and COPD-IVASC groups were exposed to cigarette smoke for 3 months and then received PBS, intratracheal injection of ASCs and intravenous
injection of ASCs, respectively. For scoring, the percent of the area containing mild, moderate or severe emphysema was multiplied by the
number 1, 2 or 3, respectively.
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significant reduction compared to the COPD-PBS animals
(P < 0.05).
Total and differential WBC counts
There was a significant increase in total WBC in the
COPD compared to the control group (P < 0.01). No
significant difference was observed between the total
WBC counts in COPD-PBS and COPD group (Figure 7A).
There was a significant increase in this parameter in the
COPD-ITASC group compared to COPD-PBS animals
but no significant difference was observed between
COPD-IVASC and COPD-PBS groups. There was no
significant difference in the number of eosinophil, neu-





















Figure 5 Thiol total concentration in broncho-alveolar lavage fluid in
compared with control group. #P < 0.05 as compared with COPD-PBS grou
COPD-ITASC and COPD-IVASC groups were exposed to cigarette smoke for
intravenous injection of ASCs, respectively.Animals weight changes
There was an increase in the weight of the animals of
control group after 3 months of ambient air exposure
but all the other groups showed a significant reduction
in this parameter after 3 months of cigarette smoking
except for COPD-IVASC group in which this increase
wasn’t significant (Figure 8). After the surgery and injec-
tion of stromal cells or PBS, all the three groups showed
a significant increase in animals’ weight during the two
weeks before being euthanized.
Discussion
In many studies pertaining to asthma and COPD, the
most widespread small animal species used are the mice
or rats while guinea pigs are the most susceptible species
and a significant airspace enlargement happens in theirD-PBS COPD-IT ASC COPD-IV ASC
+
#
different groups. Data are shown as mean ± SEM. ***P < 0.001 as
p. +P < 0.05 as compared with COPD group. The animals in COPD-PBS,
























Figure 6 Serum concentration of malondialdehyde (MDA) in different groups. Data are shown as mean ± SEM. **P < 0.01 as compared with
control; #P < 0.05 as compared with COPD-PBS. The animals in COPD-PBS, COPD-ITASC and COPD-IVASC groups were exposed to cigarette smoke
for 3 months and then received PBS, intratracheal injection of ASCs and intravenous injection of ASCs, respectively.
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[26]. Besides, the most considerable advantage of guinea
pigs, as a respiratory disease model, its airway pharma-
cology and physiological processes of these animals are
similar to human such as the airway autonomic system,
allergic reaction and responses to agonists and antago-
nists. The other side of the coin is that using guinea pigs
in animal studies has some disadvantages too, including
absence of transgenic animals, a lack of variety in guinea
pig strains, and a noticeable axon reflex that is question-
able whether it is present in human airways or not [27].
Therefore, despite the easier procedures and lower ex-
penses in working with rats or mice, guinea pig was
chosen as an animal model of COPD in the present study.
It is documented that the structural changes consid-
ered important in COPD are as follows: destruction of
alveolar wall and existence of emphysema, alveolar space
enlargement due to emphysema, increase in alveolar
septum due to infiltration of leukocytes and penetration
of smoke particles, elastolysis and collagen fiber depos-
ition in alveolar septa and pulmonary vessel wall [16].
The major reasons for these changes caused by cigarette
smoking are inflammatory responses, oxidative damage
and changes in protease-anti protease balance. Accord-
ing to the results of the present study, emphysema was
observed in the lungs of the smoke-exposed group of
animals, so that the adjacent alveolar spaces were joined
to each other due to the parenchymal destructions and
air space enlargements were clearly observed. This is con-
sistent with other studies demonstrating physiological and
morphological changes induced by cigarette smoke in lung
of guinea pigs [16,27,28]. In the present study, treatment of
smoke exposed animals by stromal cells showed no signifi-
cant improvement in the intensity of the smoke-induced
emphysema. As all the procedure of familiarizing animals
to the new habitat, smoke exposure and cell administra-
tions took several months, it was assumed that higher ageof the animals at the end of the study might be interfering
with cell therapy. Therefore, the inconvenient histopath-
ology result might be due to the lack of regenerative mech-
anisms or decreased numbers of progenitor cells in the
lung parenchyma or a stromal vascular fraction of the
older subjects [10]. Kasper et al. also worked on MSC
properties in bone marrow; they documented that not only
these cells’ potential regeneration decreases with age but
also their migration capability and number in bone marrow
decreases as an individual grows older [29]. Furthermore,
the number of systemically or locally injected cells varies
from 1 × 106 to 5 × 107 in different studies on the effect of
MSCs on lung injuries [9,10,30]. Accordingly, another rea-
son of the observed result in this part of our study might
be due to the inevitable low number of injected cells. The
number of stromal cells was intentionally chosen to be low
in this experiment because in a study, carried out by Lee
et al., it was demonstrated that intravenous injection of
high number of MSC into mice contributed in embolism
in the lung which may be fatal [31]. Consistently, Furlani
et al. documented that some of their animals died of
pulmonary embolism after abdominal aorta injection of
high and low doses of MSCs (1 × 106 MSCs or 0.2 × 106),
while no death was observed in the present study [32]. In
addition, one of the most probable reasons for the absence
of improving pharmacological effects of cell therapy on
structural changes of the lung is that these changes take
place during a long period of development of COPD which
is well known to be rarely reversible. For this reason, in
further studies, the effect of cell therapy is recommended
to be examined during different stages of development of
COPD not at the end of the disease development.
The results of this study also showed increased total
WBC in the blood of smoke exposed animal and COPD-
PBS group. However, cell therapy did not affect changes
in blood total WBC. The probable reasons for the absence






































































Figure 7 Effects of adipose derived stromal cells therapy on white blood cell counts in blood of different groups. Effects of adipose
derived stromal cells (ASCs) on total white blood cell (WBC), (A) and its effect on differential WBC (B) counts. Data are shown as mean ± SEM.
The animals in COPD-PBS, COPD-ITASC and COPD-IVASC groups were exposed to cigarette smoke for 3 months and then received PBS,
intratracheal injection of ASCs and intravenous injection of ASCs, respectively.
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long period of development of COPD which is difficult to
be affected by this method of therapy. However, further
studies regarding the effect of cell therapy during different
stages of development of COPD could be of great value.
The ranges of differential WBC counts reported in this
study may seem inconsistent with normal values. How-
ever, the ranges for lymphocyte, neutrophil and eosino-
phil number are 30-80%, 20-60% and 0-7% respectively
in guinea pig which is different from human [33]. Ourprevious studies also showed similar range of differen-
tial WBC counts in guinea pigs [34,35].
In the present study, the cells injected into the trachea
or the jugular vein of the animals were traced to confirm
that they have reached the injured lung. As described be-
fore, the labeled stromal cells were detectable in the tissue
even 2 weeks after cell therapy. It is consistent with an-
other study reporting the persistence of MSCs 21 days fol-
lowing their injection into the trachea [8]. Schweitzer




































































Figure 8 Body weight in guinea pigs of different groups. Data are shown as mean ± SEM values of body weight at three time points: at the
first of the 3 months of inhalation (Week 0), on the last day of the 3 months of inhalation (Week 12) and 2 weeks after surgery (Week 14).
*P < 0.01 as compared with week 0; ##P < 0.01 and ###P < 0.001 as compared with week 12. The animals in COPD-PBS, COPD-ITASC and COPD-IVASC
groups were exposed to cigarette smoke for 3 months and then received PBS, intratracheal injection of ASCs and intravenous injection of
ASCs, respectively.
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airways of the lungs up to 21 days after injection [5]. It
seems that two weeks recovery, given to the animals after
administration of the cells, is a proper time for the stromal
cells to exert their impact either by regeneration in the
damaged tissue or by paracrine effects.
The results of the present study showed that the oxida-
tive stress was increased in the smoke exposed group both
in their BALF and serum measured by an increase in the
concentration of MDA in serum and a decrease in the
thiol groups in BALF. It is well documented that cigarette
smoke contains stable compounds that undergo redox-
cycle to form reactive oxygen species such as superoxide
radicals, hydrogen peroxide, hydroxyl radicals etc. [36].
Our results are in accordance with the study carried out
by Qamar et al., who reported the debility in antioxidant
defenses after intratracheal instillation of cigarette smoke
extract in rats [36]. Since there was no significant differ-
ence in the MDA and thiol concentration between COPD
and COPD-PBS groups, it can be concluded that the PBS
injection had no pharmacological effect on the parameter
under investigation. BALF thiol concentration of the
treated groups with intratracheal and intravenous admin-
istration of stromal cells increased significantly in COPD-
IVASC group. However, both treated groups showed
significant decrease in serum MDA concentration. These
findings confirmed the ameliorative effect of stromal cellson the oxidative damage caused by cigarette smoke.
Consistently, the antioxidant effect of mesenchymal stem
cells within the stromal-vascular fraction of subcutaneous
adipose tissue has been previously shown by Kim et al.
documenting that these cells have potent antioxidant ac-
tivity and protect HDFs from oxidative injury by decreas-
ing apoptotic cells [11].
Considering the results, although the animals were
kept in boxes with low possibility of movement and high
probability of gaining weight during three months, being
exposed to cigarette smoke during these months caused
a considerable decrease in body weight of almost all the
animals. Complied with these results, Schweitzer et al.
documented that patients affected by emphysema often
exhibit progressive respiratory symptoms and loss of
lung function culminating in respiratory failure and sys-
temic weight loss [5]. There are plenty of other studies
demonstrating the effect of cigarette smoking on body
weight loss [37,38]. In the present study, after finishing
the three months of smoke exposure, the surgery and
administration of the cells or PBS to the animals led to a
significant increase in body weight. As Schweitzer et al.
documented, therapeutic effects of adipose stem cells
aren’t restricted to the lung but also contains restoring
the weight loss sustained by guinea pigs during cigarette
smoke exposure [5]. However, the weight gain after the
surgery, in the present study, can’t be associated with
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ment was observed in the PBS receiving groups too.
Therefore, it can be concluded that smoke cessation and
lower mobility of the animals due to the surgery might
be the initial source of gaining weight.
In the present study, the applied method of exposing
the animals to cigarette smoke resulted in exposure of
all the animals to the same concentration of cigarette
smoke as follows; every 30 second a twenty ml puff of
smoke was dragged into the head chamber using a
20 ml syringes and duration of exposure of the animals
to each cigarette was about 8 minutes with the same
duration of rest between each two successive cigarettes.
This protocol was maintained during the whole proced-
ure and the smoke concentration in the head chamber
was maintained the same for all the groups. This obvi-
ously leads to the similar levels of plasma nicotine and
its metabolite as well as similar levels of plasma carboxy-
hemoglobin. Therefore, the variations observed in the
results of different groups are just due to the variations
in treatment protocol between them.
Conclusions
In conclusion, both intratracheal and intravenous cell ther-
apy lead to pharmacological effect on reduction of oxida-
tive damage and restoring the weight loss during smoking
which may collectively hold promise in attenuation of the
severity of the disease in the patients experiencing COPD
although the lung structural changes couldn’t be amelio-
rated with these therapeutic methods. However, more
investigations are needed to further assess the pharmaco-
logical effects of adipose derived stromal cells on the
microscopic structure of the damaged lung induced by
cigarette smoke.
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